About Agomab

Agomab- A growth factor biology drug development leader

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in organ failure and fibrotic diseases.

“We are determined to improve the lives of patients through innovation. With a broad European footprint, we have built a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”


Tim Knotnerus, Chief Executive Officer


A unified team of experienced leaders providing the basis for
scientific, clinical, and corporate success

Chief Executive Officer
Chief Medical Officer
Chief Development Officer
Chief Scientific Officer
Chief Financial Officer
General Counsel
Chief Business Officer
Head of Portfolio Management
Head of R&D Operations
Head of Research
Board of Directors

The resources and guidance supporting our progress

Chairman of the Board
Chief Executive Officer


US Funds

European Funds

The Agomab team has built a strong scientific foundation in targeting growth factors and modulating related molecular pathways through novel monoclonal antibodies and small molecule compounds to resolve fibrosis, regenerate tissue and restore organ functionality. We are working with leading academic institutions and industrial partners to develop treatment options for patients.
*The Center for Industrial Technological Development (CDTI) has granted financing for the Project Origo GI “Discovery and development of new immunotherapies for organ restricted treatment of colorectal cancer and Crohn’s disease”, within its 2019 NEOTEC program.(File number EXP-00122753/SNEO-20191050) This project has been funded by the CDTI within the State Subprogram for Corporate R&D and innovation within the State Plan Framework for Scientific and Technology Research and Innovation 2017-2020 and supported by the Spanish Ministry of Economy, Industry and Competitiveness.

**The Secretary of State for Research, Development and Innovation and the Presidency of the State Research Agency has funded in the form of a loan the Project Origo GI “Discovery and development of new Immuno-Oncological and anti-fibrotic treatments with local effect – File: RTC2019-007449-1” in the 2019 call for R&D Projects « Challenges -Collaboration» of the State Program for Research, Development and Innovation Oriented to the Challenges of Society, within the framework of the State Research Plan Scientific and Technical and Innovation 2017-2020.

Become a partner or investor.

We further aim to combine our internal scientific and development expertise with leading partners to expand our therapeutic programs and combine strengths to meet some of the most pressing needs in medicine. For more information on partnering and collaborating with us, reach out to partnering@Agomab.com